The EU have always been a bit sceptical of it
The European Medicines Agency's job is to be sceptical until they have evaluated the evidence supplied. Just like the MHRA or the DFA. EMA took slightly longer over evaluating the evidence for all the vaccines but all national equivalents put approvals processes on fast track due to the emergency.
Individual EU countries have different roll out programmes and priorities because they all run their own show. Some were initial cautious of the vaccines in age groups where no testing had been carried out (at that time).
it is possible to have a different second vaccine in the UK but its by exception and AFAICR only on medical advice. Other European countries and US states have mixed the vaccines by intent from early on because it may give better overall protection. There are trials going on to try and establish this but most of them are small for disaggregated data.
The data on the small number of clotting cases suggest a bias toward younger and female so it makes sense to take the precaution of directing them to a vaccine which currently doesn't show clotting in those groups. The risk also shifts in these groups for bad consequences of COVID. It also makes sense to give all patients vaccinated clear symptoms to look out for as early warning signs. It also reinforces the case for clearly disaggregated data.
FWIW OP, I'm a bit older than you, I had a grotty reaction to first round AZ but I'll still be bang on time to get my second jab because the risk from the jab is vastly less for me than the risk of the disease. My DC will look at the latest data when they get the call (if they have a choice of jabs).
A lot of the problems arise when governments want to give a simplistic message "its totally safe" when a very slightly more nuanced message prepares the public for the very tiny risk.